Bailard Inc. Acquires 576 Shares of Eli Lilly and Company (NYSE:LLY)

Bailard Inc. grew its position in Eli Lilly and Company (NYSE:LLY) by 4.6% during the 4th quarter, Holdings Channel reports. The firm owned 12,987 shares of the company’s stock after purchasing an additional 576 shares during the quarter. Bailard Inc.’s holdings in Eli Lilly and Company were worth $7,570,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in LLY. BIP Wealth LLC lifted its holdings in Eli Lilly and Company by 45.5% during the 4th quarter. BIP Wealth LLC now owns 896 shares of the company’s stock valued at $522,000 after purchasing an additional 280 shares during the last quarter. Sycomore Asset Management raised its stake in shares of Eli Lilly and Company by 446.7% in the fourth quarter. Sycomore Asset Management now owns 4,237 shares of the company’s stock valued at $2,464,000 after acquiring an additional 3,462 shares during the last quarter. Tokio Marine Asset Management Co. Ltd. raised its stake in shares of Eli Lilly and Company by 1.2% in the fourth quarter. Tokio Marine Asset Management Co. Ltd. now owns 47,809 shares of the company’s stock valued at $27,869,000 after acquiring an additional 568 shares during the last quarter. Atria Wealth Solutions Inc. boosted its stake in Eli Lilly and Company by 5.2% in the fourth quarter. Atria Wealth Solutions Inc. now owns 44,293 shares of the company’s stock worth $25,819,000 after purchasing an additional 2,171 shares in the last quarter. Finally, Hartline Investment Corp increased its stake in shares of Eli Lilly and Company by 1.1% in the fourth quarter. Hartline Investment Corp now owns 21,934 shares of the company’s stock valued at $12,786,000 after buying an additional 248 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Insider Transactions at Eli Lilly and Company

In other news, major shareholder Lilly Endowment Inc sold 78,573 shares of the firm’s stock in a transaction dated Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total transaction of $50,920,804.11. Following the completion of the sale, the insider now owns 99,333,810 shares in the company, valued at approximately $64,375,262,246.70. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 0.13% of the stock is currently owned by corporate insiders.

Eli Lilly and Company Stock Performance

Shares of LLY traded down $7.72 during midday trading on Thursday, reaching $724.48. The stock had a trading volume of 1,868,936 shares, compared to its average volume of 3,024,208. The firm has a 50 day simple moving average of $763.40 and a 200-day simple moving average of $664.52. Eli Lilly and Company has a one year low of $370.68 and a one year high of $800.78. The firm has a market cap of $688.37 billion, a PE ratio of 124.61, a P/E/G ratio of 1.63 and a beta of 0.34. The company has a current ratio of 0.94, a quick ratio of 0.73 and a debt-to-equity ratio of 1.69.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, beating analysts’ consensus estimates of $2.30 by $0.19. The company had revenue of $9.35 billion during the quarter, compared to the consensus estimate of $8.95 billion. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The company’s quarterly revenue was up 28.1% on a year-over-year basis. During the same quarter last year, the firm posted $2.09 EPS. As a group, sell-side analysts anticipate that Eli Lilly and Company will post 12.52 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on LLY shares. Cantor Fitzgerald restated an “overweight” rating and issued a $815.00 target price on shares of Eli Lilly and Company in a research note on Monday, April 15th. Barclays lifted their price objective on Eli Lilly and Company from $680.00 to $810.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 7th. Wells Fargo & Company lifted their price objective on Eli Lilly and Company from $700.00 to $825.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 6th. TheStreet upgraded Eli Lilly and Company from a “c+” rating to a “b” rating in a research report on Friday, March 8th. Finally, Truist Financial reiterated a “buy” rating and issued a $850.00 price objective on shares of Eli Lilly and Company in a research report on Friday, March 22nd. Three analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. According to MarketBeat.com, Eli Lilly and Company has a consensus rating of “Moderate Buy” and a consensus target price of $728.05.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.